Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures ... Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital, amongst others.

The Association of Cancer Care Centers (ACCC), in collaboration with Eli Lilly and Company, is pleased to announce the seven recipients of the "Improving the Precision Oncology Care Pathway" Request ...

Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & CompanyTwo lead programs in ...

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright ...

Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time. Eli Lilly and Company (NYSE: LLY) announced results from the ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...